FilingSEC EDGAR8-K
MIRA Pharmaceuticals Completes Toxicology Studies for MIRA-55, Targets Q1 2027 IND Submission
· SEC accepted
StagePreclinical
Filing content
MIRA Pharmaceuticals completed 7-day toxicology studies of MIRA-55 in rats and dogs. The company plans to submit an IND application to the FDA in the first quarter of 2027 based on these results.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…